

VIA EXPRESS MAIL
"Express Mail" mailing label Number EL227321857115
Date of Deposit May 26, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231
FULBRIGHT & JAWORSKI L.L.P.
By: *[Signature]*

#2/A
8-17-00
M.L.

ATTY. DOCKET NO: LUD 5353.5 (10016355)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Boon, et al
Serial No. : TO BE ASSIGNED
Filed : HEREWITH
For : Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-4 and 41 And Uses Thereof
Group Art Unit : NOT YET ASSIGNED
Examiner : NOT YET ASSIGNED

May 26, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

IN THE TITLE

Change "MAGE-3" to -- MAGE-4 and 41 -- .

Claim 28. An expression vector comprising the isolated nucleic acid molecule of claim 22, operably linked to a promoter.

Claim 29. The expression vector of claim 28, wherein said promoter is an inducible promoter.

Claim 30. An expression vector comprising the isolated nucleic acid molecule of claim 25, operably linked to a promoter.

Claim 31. The expression vector of claim 30, wherein said promoter is inducible.

Claim 32. A host cell transfected or transformed with the isolated nucleic acid molecule of claim 22.

Claim 33. The host cell of claim 32, wherein said cell is a fibroblast.

Claim 34. A host cell transfected or transformed with the isolated nucleic acid of claim 25.

Claim 35. The host cell of claim 32, wherein said host cell is a mammalian cell.

Claim 36. The host cell of claim 34, wherein said host cell is a mammalian cell.

Claim 37. An isolated protein encoded by the isolated nucleic acid molecule of claim 22.

REMARKS

Entry of the foregoing amendment is requested. The changes to the specification are minor. For example, review of page 44 will show that, on line 30, "TRAP fragments" is recited, so the change to line 33 is appropriate.

This application properly claims priority to, inter alia, Serial No. 807,043, filed December 12, 1991. A review of that application will show that the examiner required applicants


to elect a species of MAGE, and applicants elected MAGE-1. In the present case, MAGE-4 and 41 are elected. In view of the examiner's action, double patenting does not lie.

Claim 22, and hence all other claims, are supported via, e.g., page 34, lines 24-28 of the specification.

Entry of the foregoing amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000

009250-24562560